Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131681) titled 'Efficacy and Safety of Iparomlimab and Tuvonralimab Combined With Capecitabine Chemotherapy as Postoperative Adjuvant Therapy for Patients With Radically Resected Cholangiocarcinoma' on Sept. 5.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The second affiliated hospital of Zhejiang University school of medicine
Condition:
Biliary tract cancers include intrahepatic cholangiocarcinoma, gallbladder carcinoma, perihilar cholangiocarcinoma, and distal cholangiocarcinoma.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-09-15
Target Sample Size: Tri...